Scarica l'app Stockscreener
2.05
0.97%
-0.02
Precedente Chiudi:
$2.07
Aprire:
$2.04
Volume 24 ore:
2,169
Relative Volume:
0.03
Capitalizzazione di mercato:
$6.50M
Reddito:
$960.60K
Utile/perdita netta:
$-7.10M
Rapporto P/E:
-0.2712
EPS:
-7.56
Flusso di cassa netto:
$-8.00M
1 W Prestazione:
-2.38%
1M Prestazione:
-10.48%
6M Prestazione:
-44.89%
1 anno Prestazione:
-66.55%
Intervallo 1D:
$2.04
$2.07
Intervallo di 1 settimana:
$1.97
$2.10
Portata 52W:
$1.68
$14.83
Soligenix Inc Stock (SNGX) Company Profile
Nome
Soligenix Inc
Settore
Industria
Telefono
609-538-8200
Indirizzo
29 EMMONS DRIVE, PRINCETON
Confronta SNGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
2.05 | 6.50M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.17 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
592.46 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.44 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
239.38 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.25 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-07-28 | Downgrade | Dawson James | Buy → Neutral |
| 2018-01-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | Reiterato | Maxim Group | Buy |
| 2017-07-17 | Iniziato | H.C. Wainwright | Buy |
Soligenix Inc Borsa (SNGX) Ultime notizie
Soligenix (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat - The Globe and Mail
Soligenix (NASDAQ: SNGX) Announces Positive Data, Continued Advancement of HyBryte(TM) - The Globe and Mail
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ f - GuruFocus
SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses… - MSN
Soligenix Announces Positive Data For Extended HyBryte In Early-stage Cutaneous T-cell Lymphoma - Nasdaq
Soligenix (SNGX) Reports Promising Interim Results for HyBryte i - GuruFocus
Positive Outcome in 75% of CTCL Patients Treated with HyBrytetm for 18 Weeks - Lelezard
Soligenix IncPositive Outcome In 75% Of Ctcl Patients Treated With Hybryte For 18 Weeks - marketscreener.com
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks - Finansavisen
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks (PR Newswire) - Aktiellt
Behcet's Disease Market to Show Remarkable Growth Trends from - openPR.com
Behcet’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Soligenix, Chugai Pharma, UMC Utrecht, Ganzhou Hemay Pharma, Amgen - The Globe and Mail
Soligenix (NASDAQ: SNGX) Spotlighted In Zacks Small-Cap Research Report, Earns $35 Valuation - Barchart.com
Soligenix (NASDAQ: SNGX) Spotlighted in Zacks Small-Cap Research Report, Earns $35 Valuation - The Globe and Mail
SNGX stock touches 52-week low at $1.74 amid market challenges - Investing.com Canada
SNGX stock touches 52-week low at $1.74 amid market challenges By Investing.com - Investing.com South Africa
Soligenix (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment - Barchart.com
Zacks Small Cap Decreases Earnings Estimates for Soligenix - The AM Reporter
Zacks Maintains $35.00 Price Per Share Valuation for Soligenix (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress - Barchart.com
Q1 Earnings Forecast for Soligenix Issued By Zacks Small Cap - Defense World
SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19… - Yahoo Finance
CiVax booster shows broad COVID-19 variant protection By Investing.com - Investing.com South Africa
IBN Initiates Coverage of Soligenix Inc. - GlobeNewswire
First National Financial Corporation to Host First Quarter Earnings Call on April 30, 2025 - The Globe and Mail
CiVax booster shows broad COVID-19 variant protection - Investing.com
Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants - PR Newswire
Soligenix (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results - The Globe and Mail
Soligenix Inc. (SNGX) reports earnings - Quartz
SOLIGENIX, INC. SEC 10-K Report - TradingView
Soligenix Trumps Year-End Financials - Baystreet.ca
Soligenix reports progress and 2024 financials By Investing.com - Investing.com Australia
Soligenix reports progress and 2024 financials - Investing.com India
Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results - Quantisnow
Soligenix Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Soligenix Financial Results Reveal Widening Losses While Clinical Pipeline Expands - StockTitan
Why Soligenix (NASDAQ: SNGX) Is ‘One to Watch’ - The Globe and Mail
Soligenix (SNGX) Expected to Announce Earnings on Friday - The AM Reporter
Soligenix Inc expected to post a loss of 95 cents a shareEarnings Preview - TradingView
Soligenix (SNGX) Projected to Post Earnings on Friday - Defense World
Soligenix (NASDAQ: SNGX) Is ‘One to Watch’ - The Globe and Mail
Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’ - Financial Content
AllPennyStocks.com News: A Steady Stream of News and Developments Pushes Soligenix Near 52 Week High - ACCESS Newswire
Soligenix, Inc. (NASDAQ:SNGX) Sees Large Decrease in Short Interest - Defense World
HyBryte™ Treatment Studies Presented at Two Medical Conferences in March - Yahoo Finance
Soligenix (SNGX) Projected to Post Quarterly Earnings on Thursday - Defense World
BiomednewsbreaksSoligenix Inc. (SNGX) To Present Hybrytetm And SGX302 Data At Dermatology Conferences - MENAFN.COM
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Soligenix Aims To Push The Boundaries In Treating Rare Diseases - The Globe and Mail
Soligenix Inc Azioni (SNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.35%
2.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):